A U.S. court on Friday denied a motion by Teva Pharmaceutical Industries for summary judgment in the Copaxone patent infringement lawsuit it has brought against Mylan Inc.    

Teva is suing generic drugmaker Mylan for infringement of patents covering Teva's top-selling Copaxone multiple sclerosis drug.      

Mylan said on Friday that the U.S. District Court for the Southern District of New York has denied Teva's motion for summary judgment.      

In addition, the court set a start date of July 11 for the trial regarding Mylan's inequitable conduct affirmative defense.      

The remaining issues will be tried beginning Sept. 7, Mylan said in a statement.      

The potential for a generic Copaxone is a major issue weighing on shares of Israel-based Teva.